WAVE Life Sciences Ltd
WVEHealthcare|Biotechnology|Singapore
$6.26
-0.07 (-1.03%)
Tangible Book
$2.66
Clinical Trials (15)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04906460 Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) | Duchenne Muscular Dystrophy | P1P2 | Recruiting | 26 | Open-label | WVE-N531 |
| NCT06842186 A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity | Overweight and Obesity | P1P2 | Recruiting | 296 | RCT, Double-blind | WVE-007 |
| NCT06405633 A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD | Alpha-1 Antitrypsin Deficiency | P1P2 | Active | 24 | Open-label | WVE-006 |
| NCT03907072 Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | P2P3 | Terminated | 6 | RCT, Double-blind | WVE-210201 (suvodirsen), Placebo |
| NCT03225846 Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease | Huntington's Disease | P1P2 | Terminated | 88 | RCT, Double-blind | WVE-120102, Placebo |
| NCT07209332 Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | P2 | By Invite | 175 | Open-label | WVE-N531 |
| NCT04617847 Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease | Huntington Disease | P1P2 | Terminated | 27 | Open-label | WVE-120101 |
| NCT03225833 Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease | Huntington's Disease | P1P2 | Terminated | 61 | RCT, Double-blind | WVE-120101, Placebo |
| NCT05032196 Study of WVE-003 in Patients With Huntington's Disease | Huntington Disease | P1P2 | Completed | 47 | RCT, Double-blind | SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003, SAD: Pooled Placebo, MD: 30mg WVE-003, MD: Placebo |
| NCT04617860 Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease | Huntington Disease | P1P2 | Terminated | 36 | Open-label | WVE-120102 |
| NCT05683860 Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) | ALS, FTD | P1P2 | Terminated | 8 | Open-label | WVE-004 |
| NCT04931862 Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) | ALS, FTD | P1P2 | Terminated | 35 | RCT, Double-blind | WVE-004, Placebo |
| NCT06186492 A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) | Alpha-1 Antitrypsin Deficiency (AATD) | P1 | Completed | 47 | RCT, Double-blind | WVE-006 |
| NCT03508947 Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | P1 | Completed | 36 | RCT, Double-blind | WVE-210201, Placebo |
| NCT03680365 Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families | Duchenne Muscular Dystrophy, Burden, Dependency | Completed | 60 | — | — |